Research·October 20, 2026 at 7:14 AM EDT·1 source
Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study
RAPP -2.3%JNJ
RAPP · last 30 trading days-9.3% since the news
News
What happened
- Rapport Therapeutics said its investigational oral AMPA-receptor drug cleared a Phase 2 study in bipolar mania.
- The company said registrational studies are slated to start next year.
- Rapport licensed the drug from Johnson & Johnson.
Why it matters
Positive mid-stage data may support Rapport’s progression toward registrational studies and increase attention on its development and licensing strategy.
What to watch. Registrational studies are slated to start next year.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 13J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business
- EarlierOct 13Health Care Roundup: Market Talk
- EarlierOct 13J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- EarlierOct 14Six Flags Entertainment Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Six Flags Entertainment (FUN)
- First reported by Endpoints NewsOct 20Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study
Who is involved
Rapport says drug it licensed from J&J clears Phase 2 bipolar…Rapport TherapeuticsRAPPJohnson & JohnsonJNJ
Company
Sources (1)
- Endpoints NewsOct 20Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study
Related
- Oct 23 · How a transatlantic mega-merger fell apart over a leadership tug of war
- Oct 13 · Health Care Roundup: Market Talk
- Oct 14 · Six Flags Entertainment Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Six Flags Entertainment (FUN)
- Oct 13 · J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- Oct 13 · J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business
- Oct 13 · J&J Leans Toward Ortho Spinoff as Medtech Sales Disappoint
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.